Epidemiological Evaluation of Patients Diagnosed with Lymphoma and the Retrospective Evaluation of the Endocrinological Parameters as Late Side Effect of the Patients Without the Treatment


Creative Commons License

Arslan B., Oner A. F., Erseçkin A., Karaman K.

Eastern Journal of Medicine, cilt.30, sa.4, ss.590-595, 2025 (Scopus, TRDizin) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 4
  • Basım Tarihi: 2025
  • Doi Numarası: 10.5505/ejm.2025.96237
  • Dergi Adı: Eastern Journal of Medicine
  • Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.590-595
  • Anahtar Kelimeler: Bone metabolism, Lymphoma, Puberty, Thyroid function
  • Van Yüzüncü Yıl Üniversitesi Adresli: Evet

Özet

In this study, it was aimed to retrospectively evaluate the epidemiological characteristics and long-term side effects related to hormon and bone metabolism in the follow-up of lymphoma patients between the ages of 0-18 years. 98 patients who were diagnosed with HL and NHL between 2007-2020 in the Van Yuzuncuyil University Pediatric Hematology Clinic were retrospectively scanned from the hospital database. The mean age of children was 96 months. It was determined that 74 (75.5%) children were boys and 24 (24.5%) were girls. No statistically significant difference was found in terms of age at diagnosis, and gender distribution of children diagnosed with HL and NHL (p=0.347, p=0.095, respectively). 25 OH vit-D deficiency was found in 21 (84%) children with a diagnosis of HL and 10 (71.4%) children with a diagnosis of NHL (p=0.187). Growth and developmental delay was found in 2 (2%) children with a diagnosis of HL. Early puberty was observed in 4 (4.1%) children, and delayed puberty was detected in 3 (5.5%) children. The median TSH, 25 OH vit-D levels and puberty findings were similar in NHL and HL group (p=0.241, p=0.399, p=0.505, respectively). Hypothyroidism was 5.1% before C hT-RT, it increased to 11.1% after ChT-RT. However, this difference was not statistically significant (p=0.241). We conclude that it is important to evaluate patients regularly in terms of endocrinological and metabolic side effects related to ChT and RT during the treatment process and long-term follow-up.